LEVER's EXTRA-STRENGTH AIM HAS NEW NDAed PRODUCT DIFFERENTIATION
Executive Summary
LEVER's EXTRA-STRENGTH AIM HAS NEW NDAed PRODUCT DIFFERENTIATION with a 1.2% sodium monofluorophosphate content. The OTC dentifrice is indicated for dental caries prophylaxis. Other OTC dosages for fluoride dentifrices have traditionally been in the .76%-.87% range. Differentiation is a key marketing tool in the oral hygiene consumer products area, as evidenced by recent product claims for gingivitis and plaque control. Lever Brothers had no comment on the recent approval.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth